A quantitative HPLC method for simultaneous determination of prodrug of voriconazole and voriconazole in beagle plasma, and its application to a toxicokinetic study

• Autorzy: Wen Yufa , Chen Shuang , Yuan Yanjuan , Shao Qing , He Xuejun , Qiao Hongqun

Identyfikatory

DOI

10.1556/1326.2021.00886

• Języki publikacji: EN

Abstrakty

EN

A simple, rapid, efficient and reproducible method based on High Performance Liquid Chromatography (HPLC) for simultaneous determination of prodrug of voriconazole (POV) and voriconazole in beagle plasma has been established and validated. Omeprazole was utilized as the sole internal standard. Analytes and internal standards were extracted through protein precipitation and separated on a Venusil XBP C18 chromatography column (4.6 × 250 mm, 5 µm). The mobile phase was methanol and 20 mmol/L potassium dihydrogen phosphate. Chromatographic separation was achieved by using an isocratic elution procedure that used 65% methanol and a flow rate of 1 mL/min. The ultraviolet (UV) detection wavelength was 256 nm and the total running time was 15 min. This method showed good linear ranges of 100–75,000 ng/mL for voriconazole prodrug and 200–100,000 ng/mL for voriconazole respectively. The precision and accuracy were acceptable. Analytes in plasma samples are stable under different temperatures and storage conditions. The developed HPLC method has been successfully applied to the studies of toxicokinetics of POV after intravenous drip in beagle and provided important information for the further development and application.

Słowa kluczowe

EN

voriconazole prodrug; voriconazole; water solubility; toxicokinetics; beagle; intravenous drip

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2022
• Tom: Vol. 34, no. 2
• Strony: 162--169
• Opis fizyczny: Bibliogr. 23 poz., rys., tab.

Twórcy

autor

Wen Yufa

• Nanjing Tech University, Nanjing 211816, China

autor

Chen Shuang

• Nanjing Tech University, Nanjing 211816, China

autor

Yuan Yanjuan

autor

Shao Qing

• Jiangsu Provincial Institute of Materia Medica, Nanjing 211816, China

autor

He Xuejun

• Nanjing Tech University, Nanjing 211816, China

autor

Qiao Hongqun

• Nanjing Tech University, Nanjing 211816, China

• https://orcid.org/0000-0003-1541-9202

Bibliografia

• 1. Jeu, L.; Piacenti, F. J.; Lyakhovetskiy, A. G.; Fung, H. B. Clin. Ther. 2003, 25, 1321–81.
• 2. Purkins, L.; Wood, N.; Greenhalgh, K.; Allen, M. J.; Oliver, S. D. Br. J. Clin. Pharmacol. 2003, 56, 10–6.
• 3. Purkins, L.; Wood, N.; Ghahramani, P.; Love, E. R.; Eve, M.; Fielding, A. Br. J. Clin. Pharmacol. 2003, 56, 37–44.
• 4. Muldrew, K. M.; Maples, H. D.; Stowe, C. D.; Jacobs, R. F. Pharmacotherapy 2005, 25, 893–8.
• 5. Johnson, L. B.; Kauffman, C. A. Clin. Infect. Dis. 2003, 36, 630–7.
• 6. Sanati, H.; Belanger, P.; Fratti, B.; Ghannoum, M. Antimicrob. Agents. Ch. 1997, 41, 2492–6.
• 7. Park, S. Y.; Yoon, J. A.; Kim, S. H. Korean J. Intern. Med. 2017, 32, 805–12.
• 8. Füredi, P. ; Pápay, Z. E. ; Kovács, K. ; Kiss, B. D. ; Ludányi, K. ; Antal, I. ; Klebovich, I. J. Pharmaceut. Biomed. 2017, 132, 184–189.
• 9. Luke, D. R.; Tomaszewski, K.; Damle, B.; Schlamm, H. T. J. Pharm. SCI-US. 2010, 99, 3291–301.
• 10. Rajewski, R. A.; Traiger, G.; Bresnahan, J.; Jaberaboansari, P.; Stella, V. J.; Thompson, D. O. J. Pharm. Sci. 1995, 84, 927–32.
• 11. Damle, B. Nephrol. Dial. Transol. 2012, 27, 1207–12.
• 12. Kiser, T. H.; Fish, D. N.; Aquilante, C. L., et al. Critical. Care. 2015, 19, 32.
• 13. Freeman, S.; Ross, K. C. J. Med. Chem. 1997, 34, 111–47.
• 14. Rautio, J.; Kumpulainen, H.; Heimbach, T., et al. Nat. Rev. Drug. Discov. 2008, 7, 255–70.
• 15. Shirali, A.; Sriram, M.; Hall, J. J.; Nguyen, B. L.; Guddneppanavar, R.; Hadimani, M. B. J. Nat. Prod. 2009, 72, 414–21.
• 16. Kumpulainen, H. ; Järvinen, T. ; Mannila, A. ; Leppänen, J. ; Nevalainen, T. ; Mäntylä, A. ; Rautio, J. Eur. J. Pharm. Sci. 2008, 34, 110–117.
• 17. Stella, V. J.; Nti-Addae, K. W. Adv. Drug. Deliver. Rev. 2007, 59, 677–94.
• 18. Shaanxi Synthetic Pharmaceutical Co., Ltd. CN Pat., CN 107652325 A, 2018.
• 19. Srinubabu, G.; Raju, C. A. I.; Sarath, N. Talanta 2007, 71, 1424–9.
• 20. Chawla, P. K.; Dherai, A. J.; Ashavaid, T. F. Indian J. Biochem. Biophys. 2015, 31, 209–14.
• 21. Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation. US, 2013.
• 22. Juemin, C.; Jing, L.; Bo, Z., et al. Regul. Toxicol. Pharm. 2019, 104, 8–13.
• 23. Pfifizer. FDA Antiviral Drugs Advisory Committee Briefifing Document for Voriconazole (Oral and Intravenous Formulations); FDA, Rockville, MD, 2001. http://www.fda.gov/ohrms/dockets/AC/01/briefifing/3792b2_01_Pfifizer.pdf, Accessed date: 15 January 2008.

Uwagi

Opracowanie rekordu ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023).